Company intelligence / Profile preview

Lucy Therapeutics

Waltham, Massachusetts, United Stateslucytherapeutics.com ↗

Ownership: Public · LSDI
Employees: ~50
Development stage: Preclinical

Overview

Lucy Therapeutics has validated neuroprotective effects of its small molecule candidates in multiple animal models for CNS diseases. The company has identified development candidates for both Rett syndrome and Parkinson's programs. IND filings are planned for all three lead programs in Alzheimer’s, Parkinson’s, and Rett syndrome in or after 2025; no clinical results have been reported yet as the company remains preclinical.

Therapeutic areas: Neurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

2 assets

LucyTx-1209

Preclinical

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $906.9K
Total revenue: $9.7K
Enterprise value: $2.1M

Beyond the preview

Go deeper on Lucy Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lucy Therapeutics.

Explore the full profile